Skip to main navigation
Pharvaris N.V logo
Main Menu

Header Nav

  • Our science
  • our pipeline
  • disease focus: HAE
  • HAE community
  • clinical trials
  • About us
    • about us
    • join us
    • Contact
  • Investors
Investor Menu

IR Nav

  • Overview
  • News & Events
    • News Releases
    • Events & Presentations
    • Publications
  • Financials
    • SEC Filings
  • Stock
    • Stock Performance
    • Analyst Coverage
  • Corporate Governance
    • Governance Documents
    • Management Team
    • Board of Directors
    • Committee Composition
  • Resources
    • FAQ
    • Contact Us
    • Email Alerts

Publications

Breadcrumb

Home / Investor Relations / NEWS & EVENTS / NEWS & EVENTS >> Publications
Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist
Nov 13, 2022
Presentation 937.4 KB
Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks
Nov 12, 2022
Presentation 818.4 KB
Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema
Oct 07, 2022
Presentation 920.1 KB
Development of PHA121 for On-Demand and Prophylactic Treatment of HAE
Sep 16, 2022
Presentation 926.6 KB
Tailored drug development for patients living with HAE
Jun 07, 2022
Presentation 1.6 MB
Pharmacological profile of PHA121 published in International Pharmacology
Mar 22, 2022
Publication
Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema
Jun 10, 2021
Poster 535.7 KB
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE
Jun 04, 2021
Presentation 4.9 MB
Presentation 38.7 MB
Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE
Feb 26, 2021
Poster 1.9 MB
PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans
Nov 13, 2020
Poster 746.5 KB
Presentation
Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema Treatment
Nov 13, 2020
Poster 664.1 KB
Presentation
In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist
Jul 30, 2020
Publication 1.7 MB
PHA-022121, a First in Class Oral Bradykinin B2 Receptor Antagonist in Clinical Development: Proof of Concept Study in a Translational Monkey Bradykinin Challenge Model
Apr 09, 2020
Poster 931.5 KB

Toolkit

Print Page
Print Page
Email Alerts
Email Alerts
IR Contacts
IR Contacts

Footer Links

Privacy     Cookie notice     Terms of Use

Social Links

  • Pharvaris 2020 - © All rights reserved